China has a thriving biotech venture capital scene, with firms bagging impressive cash in the last few years. Check out our pick of five private healthcare biotech companies that have raised major rounds in China.
Big Pharma's cancer immunotherapies were once again excluded from China's national reimbursement. Biocon and Viatris are reportedly considering combining their biosimilar operations. A Chinese oncology biotech just secured a handsome $200 million series A. And more.